Research

Cellular

GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy.

Clinicians should monitor patients on GLP-1 RAs for signs of gastroparesis and intussusception.

StrongSupportsmedium confidence
GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy.
Chengu Niu et al. · The American Journal of Gastroenterology · 2025

Why this rating

Based on a large retrospective cohort study design.

Source

Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes

Chengu Niu et al. · The American Journal of Gastroenterology · 2025

DOI 10.14309/ajg.0000000000003760

cohort · n=460830Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →